Highlights Sanofi Borsa Italiana

Equities

1SAN

FR0000120578

Real-time Estimate Tradegate Other stock markets 12:37:47 2024-07-02 EDT			5-day change	1st Jan Change
90.66 ^EUR	+2.95%		-2.81%	-1.59%

06:12pm	Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount	MT
01:36pm	SANOFI : Jefferies reaffirms its Buy rating	ZD

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Top Midday Stories: Tesla, GM Report Vehicle Deliveries; Biden, Sanders Say Novo Nordisk, Eli Lilly Charge 'Unconscionably' High Prices; Warner Bros. Interested in Deal With Paramount	12:12pm	MT
Delaware Judge Rejects Drugmakers' Appeal to End Zantac Lawsuits	06:24am	MT
Drugmakers' appeal to end Zantac cancer lawsuits rebuffed by judge	06:37pm	RE
Sanofi could invest up to EUR1.5 bn in its German insulin production site-source	07-01	RE
Sanofi eyes German insulin investment of up to $1.6 bln, source says	07-01	RE
Sector Update: Health Care Stocks Mixed Premarket Monday	07-01	MT
'HB': Sanofi plans to invest billions in Frankfurt	07-01	DP
Sanofi Eyes Up to $1.61 Billion Investment at German Production Site	07-01	MT
Sanofi Mulls Up to EUR1.5 Billion Investment in Germany	07-01	MT
Sanofi eyes investment of up to $1.6 billion in Germany, Handelsblatt says	07-01	RE
CAC40: caution prevails ahead of crucial deadlines	06-27	CF
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	06-27	MT
Top Premarket Gainers	06-27	MT
Vigil Neuroscience Shares Soar on $40 Million Sanofi Investment	06-27	DJ
Regeneron, Sanofi Eosinophilic Esophagitis Treatment Showed Improvements for Children in Phase 3 Study	06-27	MT
Vigil Neuroscience Receives $40 Million Investment From Sanofi	06-27	MT
Sanofi: positive publication for Dupixent in NEJM	06-27	CF
Sanofi Partakes in Formation Bio's $372 Million Fundraising	06-27	MT
Regeneron Pharmaceuticals, Inc Announces Dupixent® Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine	06-26	CI
FDA approves Verona Pharma's therapy for 'smoker's lungs'	06-26	RE